Antibody Responses and Infection Prevention following the Sixth Vaccination using the BA.1 bivalent COVID-19 vaccine among Healthcare workers during the XBB variant Dominance in Japan
The effect of antibodies elicited by bivalent mRNA vaccines (original and omicron BA.1) on preventing coronavirus disease 2019 (COVID-19) onset in the presence of the XBB variant remains unknown. A prospective cohort study conducted at Chiba University Hospital examined healthcare workers who receiv...
Gespeichert in:
| Veröffentlicht in: | Japanese Journal of Infectious Diseases 2024/11/29, pp.JJID.2024.116 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | JJID.2024.116 |
| container_title | Japanese Journal of Infectious Diseases |
| container_volume | |
| creator | Yahaba, Misuzu Asano, Haruna Saito, Kengo Murata, Shota Kawasaki, Kenji Chiba, Hitoshi Yokota, Shou Yoshikawa, Hiroshi Herai, Yoriko Yamagishi, Kazutaka Shiko, Yuki Matsushita, Kazuyuki Hanaoka, Hideki Taniguchi, Toshibumi Yokote, Koutaro Nakajima, Hiroshi Ido, Eiji Igari, Hidetoshi |
| description | The effect of antibodies elicited by bivalent mRNA vaccines (original and omicron BA.1) on preventing coronavirus disease 2019 (COVID-19) onset in the presence of the XBB variant remains unknown. A prospective cohort study conducted at Chiba University Hospital examined healthcare workers who received their sixth vaccination with the Pfizer-BioNTech COVID-19 bivalent mRNA vaccine (original and omicron BA.1). Researchers quantitatively measured serum anti-spike (S) antibody levels. Participants not infected during the 60-day observation period after vaccination had significantly higher S antibody titers than those who were newly infected (27756 U/mL, 95% CI [24988–30831 U/mL] vs. 15321 U/mL, 95% CI [10824–21688 U/mL], p |
| doi_str_mv | 10.7883/yoken.JJID.2024.116 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3140893024</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3140893024</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2766-ed3bc466727ede3091267c9dfe4e1ddea9e43f6fc74d82281c54359e3bafa8163</originalsourceid><addsrcrecordid>eNpVkVtv1DAQhSMEoqXwC5CQH3lJiGOv4zzuBeiuKpVrxZvl2JOu28Re7GTL_jL-Ht7sReJpjjTfnCPNSZK3OM9KzsmHnXsEm61Wy0VW5AXNMGbPkkvMOU0LTtjzqAmlKSM5vUhehfCQ58VkgvOXyQWpGC4pJ5fJ36ntTe30Dn2DsHE2QEDSarS0DajeOIu-eNiCHWXj2tY9GXuP-jWg7-ZPv0Z3Uilj5bgfwmk3m2YY1WYr23iK5rd3y0WKK7QdYUCycxG8Btn2ayU9oCfnH8EHpAd_svg1m0XeGxkNFq6LGVYBMhat5Eba18mLRrYB3hznVfLz08cf8-v05vbzcj69SVVRMpaCJrWijJVFCRpIXuGClarSDVDAWoOsgJKGNaqkmhcFx2pCyaQCUstGcszIVfL-4Lvx7vcAoRedCQraVlpwQxAE05xXJP4_ouSAKu9C8NCIjTed9DuBc7FvTIyNiX1jYt-YwGPAu2PAUHegzzeniiLw9QA8hF7ewxmQvjeqhaOp1NtoIPKT-C_kzKq19AIs-QeLJ7Sc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3140893024</pqid></control><display><type>article</type><title>Antibody Responses and Infection Prevention following the Sixth Vaccination using the BA.1 bivalent COVID-19 vaccine among Healthcare workers during the XBB variant Dominance in Japan</title><source>J-STAGE Free</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Yahaba, Misuzu ; Asano, Haruna ; Saito, Kengo ; Murata, Shota ; Kawasaki, Kenji ; Chiba, Hitoshi ; Yokota, Shou ; Yoshikawa, Hiroshi ; Herai, Yoriko ; Yamagishi, Kazutaka ; Shiko, Yuki ; Matsushita, Kazuyuki ; Hanaoka, Hideki ; Taniguchi, Toshibumi ; Yokote, Koutaro ; Nakajima, Hiroshi ; Ido, Eiji ; Igari, Hidetoshi</creator><creatorcontrib>Yahaba, Misuzu ; Asano, Haruna ; Saito, Kengo ; Murata, Shota ; Kawasaki, Kenji ; Chiba, Hitoshi ; Yokota, Shou ; Yoshikawa, Hiroshi ; Herai, Yoriko ; Yamagishi, Kazutaka ; Shiko, Yuki ; Matsushita, Kazuyuki ; Hanaoka, Hideki ; Taniguchi, Toshibumi ; Yokote, Koutaro ; Nakajima, Hiroshi ; Ido, Eiji ; Igari, Hidetoshi</creatorcontrib><description>The effect of antibodies elicited by bivalent mRNA vaccines (original and omicron BA.1) on preventing coronavirus disease 2019 (COVID-19) onset in the presence of the XBB variant remains unknown. A prospective cohort study conducted at Chiba University Hospital examined healthcare workers who received their sixth vaccination with the Pfizer-BioNTech COVID-19 bivalent mRNA vaccine (original and omicron BA.1). Researchers quantitatively measured serum anti-spike (S) antibody levels. Participants not infected during the 60-day observation period after vaccination had significantly higher S antibody titers than those who were newly infected (27756 U/mL, 95% CI [24988–30831 U/mL] vs. 15321 U/mL, 95% CI [10824–21688 U/mL], p<0.05). The risk of infection decreased by 84% when the S antibody titer exceeded 15500 U/ml. Neutralizing antibody titers against the XBB.1.16 and XBB.1.42 variants were higher in age- and sex-matched noninfected individuals than in newly infected individuals during the post-vaccination observation period. S antibody titers were highly correlated with neutralizing antibody titers. In conclusion, after the sixth COVID-19 vaccination with the bivalent mRNA vaccine (original and omicron BA.1), high S antibody titers correlated with disease prevention, even in the presence of XBB variants.</description><identifier>ISSN: 1344-6304</identifier><identifier>ISSN: 1884-2836</identifier><identifier>EISSN: 1884-2836</identifier><identifier>DOI: 10.7883/yoken.JJID.2024.116</identifier><identifier>PMID: 39617483</identifier><language>eng</language><publisher>Japan: National Institute of Infectious Diseases</publisher><subject>antibody responses ; BA.1 Bivalent COVID-19 vaccine ; healthcare workers ; XBB variant dominance</subject><ispartof>Japanese Journal of Infectious Diseases, 2024/11/29, pp.JJID.2024.116</ispartof><rights>2024 Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2766-ed3bc466727ede3091267c9dfe4e1ddea9e43f6fc74d82281c54359e3bafa8163</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39617483$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yahaba, Misuzu</creatorcontrib><creatorcontrib>Asano, Haruna</creatorcontrib><creatorcontrib>Saito, Kengo</creatorcontrib><creatorcontrib>Murata, Shota</creatorcontrib><creatorcontrib>Kawasaki, Kenji</creatorcontrib><creatorcontrib>Chiba, Hitoshi</creatorcontrib><creatorcontrib>Yokota, Shou</creatorcontrib><creatorcontrib>Yoshikawa, Hiroshi</creatorcontrib><creatorcontrib>Herai, Yoriko</creatorcontrib><creatorcontrib>Yamagishi, Kazutaka</creatorcontrib><creatorcontrib>Shiko, Yuki</creatorcontrib><creatorcontrib>Matsushita, Kazuyuki</creatorcontrib><creatorcontrib>Hanaoka, Hideki</creatorcontrib><creatorcontrib>Taniguchi, Toshibumi</creatorcontrib><creatorcontrib>Yokote, Koutaro</creatorcontrib><creatorcontrib>Nakajima, Hiroshi</creatorcontrib><creatorcontrib>Ido, Eiji</creatorcontrib><creatorcontrib>Igari, Hidetoshi</creatorcontrib><title>Antibody Responses and Infection Prevention following the Sixth Vaccination using the BA.1 bivalent COVID-19 vaccine among Healthcare workers during the XBB variant Dominance in Japan</title><title>Japanese Journal of Infectious Diseases</title><addtitle>Jpn J Infect Dis</addtitle><description>The effect of antibodies elicited by bivalent mRNA vaccines (original and omicron BA.1) on preventing coronavirus disease 2019 (COVID-19) onset in the presence of the XBB variant remains unknown. A prospective cohort study conducted at Chiba University Hospital examined healthcare workers who received their sixth vaccination with the Pfizer-BioNTech COVID-19 bivalent mRNA vaccine (original and omicron BA.1). Researchers quantitatively measured serum anti-spike (S) antibody levels. Participants not infected during the 60-day observation period after vaccination had significantly higher S antibody titers than those who were newly infected (27756 U/mL, 95% CI [24988–30831 U/mL] vs. 15321 U/mL, 95% CI [10824–21688 U/mL], p<0.05). The risk of infection decreased by 84% when the S antibody titer exceeded 15500 U/ml. Neutralizing antibody titers against the XBB.1.16 and XBB.1.42 variants were higher in age- and sex-matched noninfected individuals than in newly infected individuals during the post-vaccination observation period. S antibody titers were highly correlated with neutralizing antibody titers. In conclusion, after the sixth COVID-19 vaccination with the bivalent mRNA vaccine (original and omicron BA.1), high S antibody titers correlated with disease prevention, even in the presence of XBB variants.</description><subject>antibody responses</subject><subject>BA.1 Bivalent COVID-19 vaccine</subject><subject>healthcare workers</subject><subject>XBB variant dominance</subject><issn>1344-6304</issn><issn>1884-2836</issn><issn>1884-2836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpVkVtv1DAQhSMEoqXwC5CQH3lJiGOv4zzuBeiuKpVrxZvl2JOu28Re7GTL_jL-Ht7sReJpjjTfnCPNSZK3OM9KzsmHnXsEm61Wy0VW5AXNMGbPkkvMOU0LTtjzqAmlKSM5vUhehfCQ58VkgvOXyQWpGC4pJ5fJ36ntTe30Dn2DsHE2QEDSarS0DajeOIu-eNiCHWXj2tY9GXuP-jWg7-ZPv0Z3Uilj5bgfwmk3m2YY1WYr23iK5rd3y0WKK7QdYUCycxG8Btn2ayU9oCfnH8EHpAd_svg1m0XeGxkNFq6LGVYBMhat5Eba18mLRrYB3hznVfLz08cf8-v05vbzcj69SVVRMpaCJrWijJVFCRpIXuGClarSDVDAWoOsgJKGNaqkmhcFx2pCyaQCUstGcszIVfL-4Lvx7vcAoRedCQraVlpwQxAE05xXJP4_ouSAKu9C8NCIjTed9DuBc7FvTIyNiX1jYt-YwGPAu2PAUHegzzeniiLw9QA8hF7ewxmQvjeqhaOp1NtoIPKT-C_kzKq19AIs-QeLJ7Sc</recordid><startdate>20241129</startdate><enddate>20241129</enddate><creator>Yahaba, Misuzu</creator><creator>Asano, Haruna</creator><creator>Saito, Kengo</creator><creator>Murata, Shota</creator><creator>Kawasaki, Kenji</creator><creator>Chiba, Hitoshi</creator><creator>Yokota, Shou</creator><creator>Yoshikawa, Hiroshi</creator><creator>Herai, Yoriko</creator><creator>Yamagishi, Kazutaka</creator><creator>Shiko, Yuki</creator><creator>Matsushita, Kazuyuki</creator><creator>Hanaoka, Hideki</creator><creator>Taniguchi, Toshibumi</creator><creator>Yokote, Koutaro</creator><creator>Nakajima, Hiroshi</creator><creator>Ido, Eiji</creator><creator>Igari, Hidetoshi</creator><general>National Institute of Infectious Diseases</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20241129</creationdate><title>Antibody Responses and Infection Prevention following the Sixth Vaccination using the BA.1 bivalent COVID-19 vaccine among Healthcare workers during the XBB variant Dominance in Japan</title><author>Yahaba, Misuzu ; Asano, Haruna ; Saito, Kengo ; Murata, Shota ; Kawasaki, Kenji ; Chiba, Hitoshi ; Yokota, Shou ; Yoshikawa, Hiroshi ; Herai, Yoriko ; Yamagishi, Kazutaka ; Shiko, Yuki ; Matsushita, Kazuyuki ; Hanaoka, Hideki ; Taniguchi, Toshibumi ; Yokote, Koutaro ; Nakajima, Hiroshi ; Ido, Eiji ; Igari, Hidetoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2766-ed3bc466727ede3091267c9dfe4e1ddea9e43f6fc74d82281c54359e3bafa8163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>antibody responses</topic><topic>BA.1 Bivalent COVID-19 vaccine</topic><topic>healthcare workers</topic><topic>XBB variant dominance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yahaba, Misuzu</creatorcontrib><creatorcontrib>Asano, Haruna</creatorcontrib><creatorcontrib>Saito, Kengo</creatorcontrib><creatorcontrib>Murata, Shota</creatorcontrib><creatorcontrib>Kawasaki, Kenji</creatorcontrib><creatorcontrib>Chiba, Hitoshi</creatorcontrib><creatorcontrib>Yokota, Shou</creatorcontrib><creatorcontrib>Yoshikawa, Hiroshi</creatorcontrib><creatorcontrib>Herai, Yoriko</creatorcontrib><creatorcontrib>Yamagishi, Kazutaka</creatorcontrib><creatorcontrib>Shiko, Yuki</creatorcontrib><creatorcontrib>Matsushita, Kazuyuki</creatorcontrib><creatorcontrib>Hanaoka, Hideki</creatorcontrib><creatorcontrib>Taniguchi, Toshibumi</creatorcontrib><creatorcontrib>Yokote, Koutaro</creatorcontrib><creatorcontrib>Nakajima, Hiroshi</creatorcontrib><creatorcontrib>Ido, Eiji</creatorcontrib><creatorcontrib>Igari, Hidetoshi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese Journal of Infectious Diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yahaba, Misuzu</au><au>Asano, Haruna</au><au>Saito, Kengo</au><au>Murata, Shota</au><au>Kawasaki, Kenji</au><au>Chiba, Hitoshi</au><au>Yokota, Shou</au><au>Yoshikawa, Hiroshi</au><au>Herai, Yoriko</au><au>Yamagishi, Kazutaka</au><au>Shiko, Yuki</au><au>Matsushita, Kazuyuki</au><au>Hanaoka, Hideki</au><au>Taniguchi, Toshibumi</au><au>Yokote, Koutaro</au><au>Nakajima, Hiroshi</au><au>Ido, Eiji</au><au>Igari, Hidetoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody Responses and Infection Prevention following the Sixth Vaccination using the BA.1 bivalent COVID-19 vaccine among Healthcare workers during the XBB variant Dominance in Japan</atitle><jtitle>Japanese Journal of Infectious Diseases</jtitle><addtitle>Jpn J Infect Dis</addtitle><date>2024-11-29</date><risdate>2024</risdate><spage>JJID.2024.116</spage><pages>JJID.2024.116-</pages><artnum>JJID.2024.116</artnum><issn>1344-6304</issn><issn>1884-2836</issn><eissn>1884-2836</eissn><abstract>The effect of antibodies elicited by bivalent mRNA vaccines (original and omicron BA.1) on preventing coronavirus disease 2019 (COVID-19) onset in the presence of the XBB variant remains unknown. A prospective cohort study conducted at Chiba University Hospital examined healthcare workers who received their sixth vaccination with the Pfizer-BioNTech COVID-19 bivalent mRNA vaccine (original and omicron BA.1). Researchers quantitatively measured serum anti-spike (S) antibody levels. Participants not infected during the 60-day observation period after vaccination had significantly higher S antibody titers than those who were newly infected (27756 U/mL, 95% CI [24988–30831 U/mL] vs. 15321 U/mL, 95% CI [10824–21688 U/mL], p<0.05). The risk of infection decreased by 84% when the S antibody titer exceeded 15500 U/ml. Neutralizing antibody titers against the XBB.1.16 and XBB.1.42 variants were higher in age- and sex-matched noninfected individuals than in newly infected individuals during the post-vaccination observation period. S antibody titers were highly correlated with neutralizing antibody titers. In conclusion, after the sixth COVID-19 vaccination with the bivalent mRNA vaccine (original and omicron BA.1), high S antibody titers correlated with disease prevention, even in the presence of XBB variants.</abstract><cop>Japan</cop><pub>National Institute of Infectious Diseases</pub><pmid>39617483</pmid><doi>10.7883/yoken.JJID.2024.116</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1344-6304 |
| ispartof | Japanese Journal of Infectious Diseases, 2024/11/29, pp.JJID.2024.116 |
| issn | 1344-6304 1884-2836 1884-2836 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3140893024 |
| source | J-STAGE Free; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | antibody responses BA.1 Bivalent COVID-19 vaccine healthcare workers XBB variant dominance |
| title | Antibody Responses and Infection Prevention following the Sixth Vaccination using the BA.1 bivalent COVID-19 vaccine among Healthcare workers during the XBB variant Dominance in Japan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T23%3A12%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody%20Responses%20and%20Infection%20Prevention%20following%20the%20Sixth%20Vaccination%20using%20the%20BA.1%20bivalent%20COVID-19%20vaccine%20among%20Healthcare%20workers%20during%20the%20XBB%20variant%20Dominance%20in%20Japan&rft.jtitle=Japanese%20Journal%20of%20Infectious%20Diseases&rft.au=Yahaba,%20Misuzu&rft.date=2024-11-29&rft.spage=JJID.2024.116&rft.pages=JJID.2024.116-&rft.artnum=JJID.2024.116&rft.issn=1344-6304&rft.eissn=1884-2836&rft_id=info:doi/10.7883/yoken.JJID.2024.116&rft_dat=%3Cproquest_cross%3E3140893024%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3140893024&rft_id=info:pmid/39617483&rfr_iscdi=true |